Source comparison
Thymosin Beta-4 Fragment vs TB-500: Nomenclature Comparison
Understanding the relationship between Thymosin Beta-4 fragment and TB-500 requires clarity on origin, synthesis, and nomenclature conventions used across different research contexts. Thymosin Beta-4 (Tβ4) Naturally occurring in human tissues (thymus, platelet
This comparison does not assign a generated winner or score.
- Understanding the relationship between Thymosin Beta-4 fragment and TB-500 requires clarity on origin, synthesis, and nomenclature conventions used across different research contexts.
- Thymosin Beta-4 (Tβ4)
- Naturally occurring in human tissues (thymus, platelets, wound fluid)
- 43 amino acids
- Extracted from biological sources or synthesized
- Variable (biological extracts) or ≥95% (synthetic)
- The endogenous peptide—historically extracted but now primarily synthesized due to cost and purity advantages
- TB-500
- Synthetic laboratory production
- 43 amino acids (identical sequence to Tβ4)
- Solid-phase peptide synthesis (SPPS)
- ≥98% by HPLC
- Trade designation for synthetic Thymosin Beta-4—structurally and functionally identical to the natural peptide
- Tβ4 Fragment 1-15
- Synthetic truncation
- 15 amino acids (N-terminal region)
- SPPS
- ≥95%
- Contains actin-binding domain but lacks cell migration signaling region—used in mechanistic studies but not equivalent to TB-500
- Thymosin Alpha-1
- Naturally occurring thymic peptide
- 28 amino acids (completely different sequence)
- ≥98%
- Distinct peptide with immune-modulating properties—often confused with Tβ4 due to similar name but unrelated structure and function
- The key insight: Thymosin Beta-4 and TB-500 are the same 43-amino-acid sequence. The nomenclature difference reflects origin (natural vs synthetic) rather than structural variance. Research papers published before 2005 often used 'Thymosin Beta-4' when referring to biologically extracted material, while post-2005 publications predominantly use 'TB-500' to specify the synthetic product. Both terms describe the identical molecular entity with the same mechanism of action.
- Researchers should verify that any product labeled 'Thymosin Beta-4' or 'TB-500' contains the full 43-amino-acid sequence with N-terminal acetylation. Truncated fragments or analogs missing the acetyl group will not replicate the published bioactivity data. Certificates of analysis confirming molecular weight (4963.4 Da) and sequence identity are essential for experimental reproducibility.